Does Inflammation Contribute to Macular Degeneration?

Does Inflammation Contribute to Macular Degeneration?

Inflammation does contribute to macular degeneration; AMD is now widely considered a chronic, low‑grade inflammatory (“para‑inflammatory”) disease of the tissue that supports central vision.(1–3) Over time, innate and adaptive immune responses at the back of the eye shift from protective clean‑up to harmful over‑activation, accelerating retinal pigment epithelium (RPE) and photoreceptor damage.(1–4)pmc.ncbi.nlm.nih+2

How Inflammation Fits into AMD

Inflammation in AMD primarily affects the photoreceptor–RPE–Bruch’s membrane–choriocapillaris complex, the critical unit that maintains the macula’s structure and metabolism.(2,5) With aging and oxidative stress, these layers accumulate debris (including drusen), oxidized lipids, and damaged proteins that act as “danger signals” to the immune system.(1–3,6)pmc.ncbi.nlm.nih+3

Resident microglia migrate from the inner retina toward the outer retina and subretinal space, where they interact with infiltrating blood‑derived macrophages and other leukocytes.(1,2,5,7) Initially this para‑inflammatory response helps clear waste, but persistent stimulation leads to chronic inflammation that injures RPE, choriocapillaris, and photoreceptors rather than protecting them.(2,3,7)pmc.ncbi.nlm.nih+4

Inflammation also intersects closely with oxidative stress and complement activation. Oxidative damage increases inflammatory signalling, and complement fragments deposited in and around drusen further activate microglia and macrophages, creating a self‑reinforcing loop: damage triggers inflammation, which in turn causes more damage.(1–3,6,8)pmc.ncbi.nlm.nih+2

What Happens at the Cellular Level?

Microglia and macrophages

Human and animal studies show clusters of microglia and macrophages around drusen, subretinal deposits, and areas of atrophy in AMD eyes.(1,2,5,7) These cells can adopt reparative phenotypes (phagocytosing debris, secreting neurotrophic factors) or pro‑inflammatory, pro‑angiogenic phenotypes that release reactive oxygen species, proteases, and cytokines.(2,5,7)pmc.ncbi.nlm.nih+3

When chronically activated, they contribute to:

• RPE apoptosis and disruption of the outer blood–retina barrier
• Choriocapillaris dropout and thinning
• Promotion of choroidal neovascularization (CNV) and subretinal fibrosis(5,7–9)frontiersin+2

Cytokines and chemokines

Inflamed RPE, microglia, and macrophages produce cytokines such as IL‑1β, IL‑6, IL‑8, TNF‑α, and IL‑18, and chemokines such as MCP‑1 (CCL2).(1,2,4,6) These mediators:pmc.ncbi.nlm.nih+2

• Attract additional immune cells into the subretinal space
• Increase vascular permeability and stimulate VEGF production
• Interfere with RPE survival, photoreceptor function, and extracellular‑matrix stability(1,2,4,6,8)pmc.ncbi.nlm.nih+2

Experimental models show that blocking key cytokines (for example IL‑1 or TNF‑α) can reduce CNV size, whereas pushing macrophages toward a pro‑inflammatory phenotype enhances angiogenesis and scarring.(1,4,8)pmc.ncbi.nlm.nih+2

Inflammasomes (NLRP3)

The NLRP3 inflammasome is an intracellular sensor complex in myeloid cells and RPE that detects danger signals such as drusen components, complement proteins, and oxidized lipids.(4,6,10) NLRP3 activation triggers caspase‑1, which matures IL‑1β and IL‑18 and can induce pyroptotic inflammatory cell death.(4,10)open.library.ubc+2

Drusen isolated from AMD donor eyes, as well as C1q and other aggregates, activate NLRP3 and promote IL‑1β/IL‑18 release in macrophages and RPE in vitro.(4,10) Macular tissue from advanced AMD patients shows elevated NLRP3 and these cytokines, directly linking inflammasome signalling to human disease.(4,6,10)pmc.ncbi.nlm.nih+2

How Inflammatory Changes Affect Daily Vision

Inflammation itself is not felt by patients, but its consequences drive the structural changes that impair vision. In dry (atrophic) AMD, chronic inflammatory injury speeds up RPE and photoreceptor loss, leading to geographic atrophy and gradual central vision loss.(1–3) People often notice increasing difficulty reading, missing patches in central vision, and trouble in low‑contrast or dim conditions.frontiersin+2

In wet (neovascular) AMD, inflammatory cytokines and complement fragments stimulate VEGF production and choroidal neovascularization.(1,2,4,8) Fragile new vessels leak fluid and blood under or within the retina, causing sudden distortion, blurred central vision, or dark spots that can progress rapidly without treatment.(1,2) Repeated bouts of inflammation and VEGF‑driven CNV may end with subretinal fibrosis, where scar tissue replaces photoreceptors and permanently reduces visual potential.(5,7–9)pmc.ncbi.nlm.nih+5

Clinical Evidence and Risk Mitigation

Evidence that inflammation drives AMD

• Tissue and imaging studies: AMD donor eyes and imaging show microglial/macrophage accumulation, complement deposition, and inflammatory cytokines concentrated around drusen, subretinal deposits, and atrophic lesions.(1–3,5,6)pmc.ncbi.nlm.nih+3
• Inflammasome data: Drusen components, complement, and oxidative stress activate NLRP3 in RPE and macrophages, increasing IL‑1β/IL‑18 and sometimes causing pyroptosis.(4,6,10)pmc.ncbi.nlm.nih+2
• Systemic markers: Meta‑analysis and cohort studies link higher serum C‑reactive protein (CRP) and other inflammatory markers (for example IL‑6) to increased incidence of late AMD and faster progression from intermediate disease.(9–11)pubmed.ncbi.nlm.nih+2

How this shapes treatment and prevention

Current therapies already target inflammatory consequences:

• Anti‑VEGF injections suppress VEGF upregulated by inflammatory and hypoxic signalling, treating the neovascular component of wet AMD.
• Complement inhibitors for geographic atrophy (for example pegcetacoplan, avacincaptad pegol) reduce complement‑driven inflammation at the RPE–choroid interface.(8,12)pubmed.ncbi.nlm.nih+1

Risk‑reduction strategies that likely help by lowering inflammatory drive include:

• Smoking cessation, which reduces oxidative and inflammatory stress and is one of the strongest modifiable AMD risk factors.(2,3)pmc.ncbi.nlm.nih+1
• Control of cardiovascular and metabolic risk factors, which lowers systemic inflammation and is associated with slower AMD progression in some cohorts.(3,11)pmc.ncbi.nlm.nih+1
• A Mediterranean‑style diet (high in leafy greens, fruits, whole grains, and fish), which is linked to lower AMD incidence and progression and to reduced systemic inflammatory markers.(3,12)pmc.ncbi.nlm.nih+1

Emerging therapies targeting inflammasomes, specific cytokines, or microglial signalling are under investigation but are not yet standard practice.(4,8,12)sciencedirect+2

When Should Someone See a Retina Specialist?

You should consult an ophthalmologist or retina specialist if you:

• Have known drusen or early AMD and notice new central blur, distortion, or trouble reading.
• Have systemic inflammatory conditions or persistently high CRP and are concerned about eye health.
• Are being evaluated for complement‑inhibitor or other advanced AMD therapies and want to understand how inflammation might influence your treatment.

Retina specialists use optical coherence tomography (OCT), OCT‑angiography, and fundus autofluorescence to detect inflammatory signs such as hyperreflective foci (likely activated microglia/macrophages), subretinal deposits, and early atrophy, which help tailor monitoring and intervention plans.(1–3,5,6)frontiersin+3

FAQs

Is macular degeneration an inflammatory or degenerative disease?
AMD is both. Ageing and oxidative stress initiate degeneration, but persistent para‑inflammation and immune activation strongly influence how quickly degeneration progresses and whether neovascularization develops.(1–3)pmc.ncbi.nlm.nih+2

Do all people with systemic inflammation develop AMD?
No. High CRP or other inflammatory markers increase risk but do not guarantee AMD; genetics, age, smoking, diet, and ocular factors all interact to determine individual susceptibility.(3,9–11)pubmed.ncbi.nlm.nih+2

Can over‑the‑counter anti-inflammatory drugs (like ibuprofen) slow AMD?
There is no strong evidence that systemic NSAIDs or steroids slow AMD progression, and they carry potential side effects.(1–3) Current evidence supports targeted ocular treatments (anti‑VEGF, complement inhibitors) and systemic lifestyle changes rather than routine systemic anti‑inflammatory medication for AMD.pmc.ncbi.nlm.nih+2

What is the NLRP3 inflammasome and why is it important here?
The NLRP3 inflammasome is a sensor complex that detects danger signals from drusen, complement, and oxidative damage, then activates caspase‑1 to produce IL‑1β and IL‑18 and, in some contexts, pyroptotic cell death.(4,6,10) Its activation has been documented in AMD tissues and represents a promising target for future therapies.(4,10)open.library.ubc+2

Can lifestyle changes really impact such a complex inflammatory process?
Yes, to a meaningful extent. Smoking cessation, a healthy Mediterranean‑style diet, and cardiovascular risk control reduce systemic and ocular inflammatory stress and are consistently associated with reduced AMD incidence or slower progression, even though they cannot reverse existing damage.(3,11,12)pmc.ncbi.nlm.nih+1

This article is for educational purposes only and does not replace personalized advice from your eye‑care professional.

References (Vancouver style)

1. Xu H, Chen M, Forrester JV. The role of inflammation in age-related macular degeneration. Ther Adv Chronic Dis. 2020;11:2040622320925994.[pmc.ncbi.nlm.nih] 
2. Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016;73(9):1765‑1786.[pmc.ncbi.nlm.nih] 
3. Cascella R, Ragazzo M, Strafella C, et al. Age-related macular degeneration: insights into inflammatory gene regulation. J Clin Med. 2014;3(4):1542‑1560.[pmc.ncbi.nlm.nih] 
4. Wang H, Han X, Wittchen ES, Hartnett ME. Targeting inflammasomes and pyroptosis in retinal diseases. Prog Retin Eye Res. 2024;xx:xxxx.[sciencedirect] 
5. Zhang Q, Dou G, Xu H. Exploring the pathogenesis of age-related macular degeneration: focus on inflammatory cells. Front Neurosci. 2022;16:1009599.[frontiersin] 
6. Age‑Related Macular Degeneration: Insights into inflammatory mechanisms. In: Cascella R, et al. J Clin Med. 2014;3(4):1542‑1560.[pmc.ncbi.nlm.nih] 
7. Chen M, Xu H. Differential roles of macrophages and microglia in subretinal fibrosis and neovascular AMD. Invest Ophthalmol Vis Sci. 2025;xx:xxxx.[pmc.ncbi.nlm.nih] 
8. Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31.[pmc.ncbi.nlm.nih] 
9. Seddon JM, Gensler G, Klein ML, Milton RC. A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv Ophthalmol. 2010;55(6):519‑535.[pubmed.ncbi.nlm.nih] 
10. Ambati J, Atkinson JP, Gelfand BD. Immune privilege in the retina and the NLRP3 inflammasome in age-related macular degeneration. J Clin Invest. 2013;123(4):1632‑1640.[pmc.ncbi.nlm.nih] 
11. Wu Z, Ayton LN, Luu CD, et al. Association of systemic inflammatory factors with progression to advanced age-related macular degeneration. Ophthalmol Sci. 2021;1(2):100028.[pmc.ncbi.nlm.nih] 
12. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE–Bruch’s membrane interface in aging and AMD. Prog Retin Eye Res. 2001;20(6):705‑732.[pmc.ncbi.nlm.nih]